Floatz logo

Toripalimab

Liver Transplantation

Shanghai Zhongshan Hospitalmonoclonal_antibodyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Liver Transplantation cohort.

Asset / SponsorPhaseRating
TACROLIMUS
The Second Hospital of Tangshan
Phase 4BBB
Giapreza
University of California, San Francisco
Phase 4BBB
Everolimus
Novartis Pharmaceuticals
Phase 3BB
Equine Atg
University Hospital, Toulouse
Phase 4BB
Envarsus Product
University of Alberta
Phase 4BB

View all 35 →

Same molecule, other indications

Toripalimab is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
ToripalimabDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →